Cosyntropin vs hGHRH(1-37)OH
Head-to-head comparison of Cosyntropin (Cosyntropin (ACTH 1-24)) and hGHRH(1-37)OH (Human growth hormone-releasing factor (1-37) hydroxyl) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cosyntropin | hGHRH(1-37)OH |
|---|---|---|
| Category | Pain Management | Growth Hormone |
| Full Name | Cosyntropin (ACTH 1-24) | Human growth hormone-releasing factor (1-37) hydroxyl |
| Molecular Weight | 2933.3 Da | N/A |
| Half-Life | ~10 min | 5-20 minutes |
| Amino Acids | 24 | 37 |
| Typical Dose | 0.25 mg IV/IM diagnostic dose|off-label headache protocols vary | 1-2 mcg/kg |
| Route | IV|IM | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 61 | 60 |
| Research Status | Clinical research | Clinical Research |
Cosyntropin Benefits
- ✓refractory migraine
- ✓anti-inflammatory signaling
- ✓headache rescue research
hGHRH(1-37)OH Benefits
- ✓GH release studies
- ✓minimal-sequence mapping
- ✓receptor pharmacology
- ✓peptide stability research
Cosyntropin Dosing
0.25 mg IV/IM|1 mg IV/IM
hGHRH(1-37)OH Dosing
1-2 mcg/kg SC or IV bolus|acute stimulation with serial GH assays|short-course research administration with biomarker monitoring
Cosyntropin Side Effects
- ⚠flushing
- ⚠nausea
hGHRH(1-37)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠transient fatigue
Research Overview
Cosyntropin
Cosyntropin is not a standard pain drug, but it appears in headache literature because ACTH analogs can help some patients with difficult migraine attacks. The analgesic rationale is partly tied to steroidogenic and anti-inflammatory effects.
hGHRH(1-37)OH
Human GHRF(1-37)OH has appeared in studies examining how loss of C-terminal residues affects biological activity at the GHRH receptor. It is often used alongside other fragments to define structure-activity relationships within the GHRH family.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.